Stockreport

Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab [Yahoo! Finance]

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced it has be [Read more]